ADGRE1/EMR1 recombinant proteins and antibodies

Adhesion G protein-coupled receptor E1 (ADGRE1), also known as EMR1, is a G protein-coupled receptor (GPCR) that is predominantly expressed on immune cells, including eosinophils, monocytes, and dendritic cells. ADGRE1 plays a key role in regulating inflammation, immune cell migration, and activation. It interacts with ligands to activate downstream signaling pathways that influence immune cell functions, making it critical in the pathogenesis of various immune-related diseases.

Research has shown that ADGRE1 is involved in several immune diseases, such as allergic reactions, asthma, rheumatoid arthritis, and inflammatory bowel disease. Particularly in the regulation of eosinophil function, ADGRE1 significantly influences the intensity and duration of immune responses. Additionally, ADGRE1 has been implicated in immune evasion in certain cancers, making it a potential therapeutic target for cancer immunotherapy. Currently, several studies have focused on targeting ADGRE1 to develop novel immunomodulatory treatments. Inhibitors of ADGRE1 can effectively regulate immune cell activity, thereby alleviating excessive immune responses or enhancing immune surveillance against tumors. Current drug development efforts include small-molecule inhibitors and antibody therapies. With a deeper understanding of ADGRE1’s role in immune regulation, more innovative drugs targeting ADGRE1 are expected to enter clinical trials in the coming years, providing new treatment options for allergic conditions, inflammatory diseases, and certain cancers.

To assist in the development of ADGRE1 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for ADGRE1 targets. Products include active ADGRE1 recombinant proteins, full-length ADGRE1 proteins, ADGRE1 reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of ADGRE1 biotherapy, DIMA BIOTECH has also prepared a ADGRE1 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple ADGRE1 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.